It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
MicroRNAs (miRNAs) are small non-coding RNAs that play a crucial role in pathogenesis of human cancers. Several miRNAs have been shown to involve in nasopharyngeal carcinoma (NPC) pathogenesis through alteration of gene networks. A global view of the miRNA expression profile of clinical specimens would be the best way to screen out the possible miRNA candidates that may be involved in disease pathogenesis. In this study, we investigated the expression profiles of miRNA in formalin-fixed paraffin-embedded tissues from patients with undifferentiated NPC versus non-NPC controls using a miRNA real-time PCR platform, which covered a total of 95 cancer-related miRNAs. Hierarchical cluster analysis revealed that NPC and non-NPC controls were clearly segregated. Promisingly, 10 miRNA candidates were differentially expressed. Among them, 9 miRNAs were significantly up-regulated of which miR-205 and miR-196a showed the most up-regulated in NPC with the highest incidence percentage of 94.1% and 88.2%, respectively, while the unique down-regulated miR-150 was further validated in patient sera. Finally, the in vitro gain-of-function and loss-of-function assays revealed that miR-150 can modulate the epithelial-mesenchymal-transition property in NPC/HK-1 cells and led to the cell motility and invasion. miR-150 may be a potential biomarker for NPC and plays a critical role in NPC tumourigenesis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Department of Biology, Faculty of Science, Hong Kong Baptist University, Hong Kong, China
2 Center for Nasopharyngeal Carcinoma Research, University of Hong Kong, Hong Kong, China; Department of Clinical Pathology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China
3 Center for Nasopharyngeal Carcinoma Research, University of Hong Kong, Hong Kong, China; Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital, Hong Kong, China
4 Center for Nasopharyngeal Carcinoma Research, University of Hong Kong, Hong Kong, China; Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, SAR, People’s Republic of China
5 Center for Nasopharyngeal Carcinoma Research, University of Hong Kong, Hong Kong, China; Department of Oncology, Princess Margaret Hospital, Hong Kong, SAR, People’s Republic of China
6 Center for Nasopharyngeal Carcinoma Research, University of Hong Kong, Hong Kong, China; Department of Clinical Oncology and Center for Cancer Research, University of Hong Kong, Hong Kong, SAR, People’s Republic of China
7 Department of Biology, Faculty of Science, Hong Kong Baptist University, Hong Kong, China; Center for Nasopharyngeal Carcinoma Research, University of Hong Kong, Hong Kong, China
8 Center for Nasopharyngeal Carcinoma Research, University of Hong Kong, Hong Kong, China; Department of Clinical Oncology, University of Hong Kong, Hong Kong, China